Amgen Reports Safety & Efficacy Results of Repatha (evolocumab) in OSLER-1 Five-Year Extension Study
Shots:
- The OSLER-1 (Open-Label Study of Long-TERm Evaluation Against LDL-C) study involves assessing of Repatha (420 mg) + SoC or SoC alone in patients with hypercholesterolemia in ratio (2:1) across 192 sites in 18 countries
- OSLER-1 (N≤ 1324) study results: reduction in mean LDL-C @1/2/3/4/5yrs. (59%- 56%- 57%- 56%- 56%). Another study GOULD is practiced in patients with ASCVD to demonstrate levels of LDL-C in US over category: currently receiving a PCSK9i antibody- no PCSK9i and LDL-C 70-99 mg/dL- & no PCSK9i and LDL-C ≥ 100 mg/dL
- GOULD study demonstrated underutilization of LDL-C lowering treatments in high risk CV events patients and awareness of treatment goals
- Repatha is a mAb used for inhibiting PCSK9 (proprotein convertase subtilisin/kexin type 9) and is currently approved in > 60 countries including the US- Japan- Canada
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
